Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

Authors: Tiankang Guo, Jingyu Yang, Jibin Yao, Yongbin Zhang, Mingxu Da, Yaoxing Duan

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Recent studies have suggested that the metastasis-associated colon cancer1 (MACC1) gene can promote tumor proliferation, invasion and metastasis through an upregulation of c-Met expression. However, its role in gastric cancer is controversial. Our study investigated expression of MACC1 and c-Met in gastric cancer, as well as correlated this with clinicopathological parameters.

Methods

Expressions of MACC1 and c-Met protein in a sample of 98 gastric carcinoma and adjacent nontumorous tissues were detected by immunohistochemistry. Their relationships and correlations with clinicopathological features were analyzed.

Results

The positive rates of MACC1 and c-Met protein in primary tumors were 61.22% and 59.18%, respectively. A significant correlation was found between expression of MACC1 and c-Met (P<0.05). Expression of the MACC1 protein in gastric cancer tissue was correlated with lymph node metastasis (χ2 = 10.555,P = 0.001), peritoneal metastasis (χ2 = 5.694, P = 0.017), and hepatic metastasis (χ2 = 4.540,P = 0.033), but not with age, gender, tumor size, location, clinical stage or the distant metastases (P>0.05).

Conclusion

The positive rate of MACC1 protein expression was related to the protein expression of c-Met. Both had a correlation with the presence of peritoneal metastasis, lymph node metastasis and hepatic metastasis, all of which contribute to a poor prognosis for gastric cancer patients.
Appendix
Available only for authorised users
Literature
1.
Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J: Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res. 2013, 19: 111-117. 10.1007/s12253-012-9530-z.CrossRefPubMed
2.
Lin YS, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, Inoue M: Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011, 17: 4421-4428. 10.3748/wjg.v17.i39.4421.PubMedCentralCrossRefPubMed
3.
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2009, 15: 59-67. 10.1038/nm.1889.CrossRefPubMed
4.
Da MX, Wu Z, Tian HW: Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res. 2008, 39: 365-372. 10.1016/j.arcmed.2007.12.005.CrossRefPubMed
5.
Zhou HY, Pon YL, Wong AS: HGF/MET signaling in ovarian cancer. Curr Mol Med. 2008, 8: 469-480. 10.2174/156652408785747933.CrossRefPubMed
6.
Ogunwobi OO, Liu C: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis. 2011, 28 (8): 721-731. 10.1007/s10585-011-9404-x.PubMedCentralCrossRefPubMed
7.
Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N: HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 2012, 18 (2): 209-218. 10.1007/s12253-011-9430-7.CrossRefPubMed
8.
Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC: c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010, 32: 1655-1664. 10.1002/hed.21383.CrossRefPubMed
9.
Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y: c-Met expression in gastric cancer with liver metastasis. Oncology. 2002, 63: 286-296. 10.1159/000065477.CrossRefPubMed
10.
Zhang W, Chu Y-Q, Ye Z-Y, Zhao Z-S, Tao H-Q: Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec. 2009, 292: 1114-1121. 10.1002/ar.20934.CrossRef
11.
Amemiya H, Menolascino F, Pena A: Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin. 2010, 51: 369-380.PubMed
12.
Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Yasumoto K: Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg. 2011, 141: 895-898. 10.1016/j.jtcvs.2010.09.044.CrossRefPubMed
13.
Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011, 31: 1141-1145.PubMed
14.
Gu C, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res. 2011, 31: 1141-1145.
15.
Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H: MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011, 31: 777-780.PubMed
16.
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011, 9: 166-10.1186/1479-5876-9-166.PubMedCentralCrossRefPubMed
17.
Huang HL, Shi HR, Zhang RT, Chen ZM, Liu HN, Yuan ZF: Expression of MACC1 in epithelial ovarian cancer and its clinical significance. Tumor. 2011, 31: 522-526.
18.
Zhang R, Shi H, Chen Z, Wu Q, Ren F, Huang H: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res. 2011, 30: 83-10.1186/1756-9966-30-83.PubMedCentralCrossRefPubMed
19.
Boardman LA: Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med. 2009, 1: 36-10.1186/gm36.PubMedCentralCrossRefPubMed
20.
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH: Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012, 106 (3): 304-310. 10.1002/jso.23008.CrossRefPubMed
21.
Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005, 24: 2885-2895. 10.1038/sj.emboj.7600763.PubMedCentralCrossRefPubMed
22.
Zhang QH, Qian K, Li XJ, Pu J, Wu XT: Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2007, 10: 212-216.PubMed
23.
Glockzin G, Piso P: Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am. 2012, 21: 625-633. 10.1016/j.soc.2012.07.002.CrossRefPubMed
24.
Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G: MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res. 2010, 30: 3441-3444.PubMed
25.
Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M: Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 2012, 130: 2912-2921. 10.1002/ijc.26330.CrossRefPubMed
26.
van Denderen BJ, Thompson EW: Cancer: the to and fro of tumour spread. Nature. 2013, 493: 487-488. 10.1038/493487a.CrossRefPubMed
27.
Theveneau E, Mayor R: Collective cell migration of epithelial and mesenchymal cells. Cell Mol Life Sci. 2013, 70 (19): 3481-3492. 10.1007/s00018-012-1251-7.CrossRefPubMed
28.
Jerraya H, Saidani A, Khalfallah M, Bouasker I, Nouira R, Dziri C: Management of liver metastases from gastric carcinoma: where is the evidence?. Tunis Med. 2013, 91: 1-5.PubMed
29.
Kodera Y: Treatment strategy for liver metastasis from gastric cancer. Nihon Geka Gakkai Zasshi. 2012, 113: 22-25.PubMed
30.
Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, Du H, Dong B, Hu Y, Ji JF: Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Canc Res. 2011, 23: 153-159. 10.1007/s11670-011-0153-9.CrossRef
31.
Stein U, Smith J, Walther W, Arlt F: MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle. 2009, 8: 2467-2469. 10.4161/cc.8.15.9018.CrossRefPubMed
Metadata
Title
Expression of MACC1 and c-Met in human gastric cancer and its clinical significance
Authors
Tiankang Guo
Jingyu Yang
Jibin Yao
Yongbin Zhang
Mingxu Da
Yaoxing Duan
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-121

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia

Primary research

Assessment of potential anti-cancer stem cell activity of marine algal compounds using an in vitro mammosphere assay

Primary research

A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior

Primary research

Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin

Primary research

Positive association between Interleukin-8 -251A > T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis

Primary research

Restoration of klotho gene expression induces apoptosis and autophagy in gastric cancer cells: tumor suppressive role of klotho in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits